N. Milne

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes

D. Wheeler, M. Evans, J. James, 2020, Diabetes Therapy.

Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care

M. Rutter, L. Leelarathna, D. Ashcroft, 2021, BMJ Quality & Safety.

Digital Interventions Supporting Self-care in People With Type 2 Diabetes Across Greater Manchester (Greater Manchester Diabetes My Way): Protocol for a Mixed Methods Evaluation

E. Kontopantelis, S. Cunningham, J. Goldthorpe, 2022, JMIR research protocols.

Impact of COVID-19 on the diagnoses, HbA1c monitoring and mortality in people with type 2 diabetes: a UK-wide cohort study involving 13 million people in primary care

L. Leelarathna, D. Ashcroft, A. Wright, 2020, medRxiv.

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

J. Wilding, M. Evans, S. Bain, 2018, Diabetes Therapy.

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

J. Wilding, M. Evans, S. Bain, 2019, Diabetes Therapy.

Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK

M. Rutter, L. Leelarathna, D. Ashcroft, 2021, The Lancet Diabetes & Endocrinology.

An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database

J. Curtis, J. LaFleur, N. Milne, 2015, Osteoporosis International.